Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
9 Under-The-Radar Malaysian Islands To Consider Instead Of Thailand Or Indonesia - 2Skeleton of famed musketeer possibly found in Dutch church
- 3Cocoa Prices Settle Lower on Expectations of Adequate Supplies
- 4She just became the first wheelchair user to travel to space
- 5Miley Cyrus details her fear of paper, says fiancé Maxx Morando opens their packages outside: 'That's really why I got engaged'
- 'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
- IDF, police arrest eleven for criminal, terror-related activity over weekend
- As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- Moon rocket and weather are on NASA's side for the first astronaut launch in decades
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- Authentic Urban areas: Rich Legacy and Lively Societies
- Embracing Practical Living and Ecological Protection
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
